by The compounding pharmacy market size is poised to grow by USD 28.19 billion by 2032 from USD 14.92 billion in 2022, exhibiting a CAGR of 6.57% during the forecast period 2023-2032.
Key Takeaways:
- North America is expected to dominate the market during the forecast period.
- By therapeutic area, the pain management segment is expected to dominate the market over the forecast period.
- By route of administration, the oral segment is expected to hold the largest revenue share over the forecast period.
- By distribution channel, the hospital pharmacy segment is expected to dominate the market over the forecast period.
Precedence Research has conducted a comprehensive market study that provides valuable insights into the performance of the market during the forecast period. The study identifies significant trends that are shaping the growth of the Compounding pharmacy market. In this recently published report, essential dynamics such as drivers, restraints, and opportunities are highlighted for both established market players and emerging participants involved in production and supply.
To begin with, the Compounding pharmacy Market report features an executive summary that offers a concise overview of the marketplace. It outlines the key players and industry categories expected to have an impact on the market in the coming years. The executive summary provides an unbiased summary of the market.
Get a Sample Report: https://www.precedenceresearch.com/sample/3185
Compounding Pharmacy Market Report Scope
| Report Coverage | Details |
| Market Size in 2023 | USD 15.9 Billion |
| Market Size by 2032 | USD 28.19 Billion |
| Growth Rate from 2023 to 2032 | CAGR of 6.57% |
| Largest Market | North America |
| Base Year | 2022 |
| Forecast Period | 2023 To 2032 |
| Segments Covered | By Therapeutic Area, By Route of Administration, By Application, By Compounding Type, By Sterility, and By Distribution Channel |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Read More: Grow Lights Market Size To Rake USD 24.44 Bn By 2032
The empirical study on the global Compounding pharmacy market primarily focuses on the drivers in subsequent sections. It demonstrates how changing demographics are projected to influence the supply and demand dynamics in the Compounding pharmacy Market. Our market report for the Compounding pharmacy market also delves into the significant rules and regulations that are likely to impact the future growth of this sector. Moreover, in order to comprehend the underlying demand factors, industry experts have provided insights into its fundamental origins.
Top Key Players:
- Fresenius Kabi
- Fagron NV
- B. Braun Medical Inc.
- Rx3 Compounding Pharmacy
- Clinigen Group PLC
- Dougherty’s Pharmacy, Inc.
- Lorraine’s Pharmacy
- Wedgewood Pharmacy
- Institutional Pharmacy Solutions
- Mcguff compounding pharmacy services
Data Sources and Methodology
To gather comprehensive insights on the Global Compounding pharmacy Market, we relied on a range of data sources and followed a well-defined methodology. Our approach involved interactions with industry experts and key stakeholders across the market’s value chain, including management organizations, processing organizations, and analytics service providers.
We followed a rigorous data analysis process to ensure the quality and credibility of our research. The gathered information was carefully evaluated, and relevant quantitative data was subjected to statistical analysis. By employing robust analytical techniques, we were able to derive meaningful insights and present a comprehensive overview of the Global Compounding pharmacy Market.
The most resonating, simple, genuine, and important causes because of which you must decide to buy the Compounding pharmacy market report exclusively from precedence research
- The research report has been meticulously crafted to provide comprehensive knowledge on essential marketing strategies and a holistic understanding of crucial marketing plans spanning the forecasted period from 2023 to 2032.
Key Features of the Report:
- Comprehensive Coverage: The report extensively encompasses a detailed explanation of highly effective analytical marketing methods applicable to companies across all industry sectors.
- Decision-Making Enhancement: It outlines a concise overview of the decision-making process while highlighting key techniques to enhance it, ensuring favorable business outcomes in the future.
- Articulated R&D Approach: The report presents a well-defined approach to conducting research and development (R&D) activities, enabling accurate data acquisition on current and future marketing conditions.
Compounding Pharmacy Market Segmentation:
By Therapeutic Area
- Pain Management
- Hormone Replacement
- Dermal Disorders
- Nutritional Supplements
- Others
By Route of Administration
- Oral
- Topical
- Parenteral
- Others
By Application
- Pediatric
- Geriatric
- Adult
- Veterinary
By Compounding Type
- Pharmaceutical Dosage Alteration (PDA)
- Pharmaceutical Ingredient Alteration (PIA)
- Currently Unavailable Pharmaceutical Manufacturing (CUPM)
- Others
By Sterility
- Sterile
- Non-sterile
By Distribution Channel
- Compounding Pharmacy
- Hospital Pharmacy
- Others
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Reasons to Consider Purchasing the Report:
- Enhance your market research capabilities by accessing this comprehensive and precise report on the global Compounding pharmacy market.
- Gain a thorough understanding of the overall market landscape and be prepared to overcome challenges while ensuring robust growth.
- Benefit from in-depth research and analysis of the latest trends shaping the global Compounding pharmacy market.
- Obtain detailed insights into evolving market trends, current and future technologies, and strategic approaches employed by key players in the global Compounding pharmacy market.
- Receive valuable recommendations and guidance for both new entrants and established players seeking further market expansion.
- Discover not only the cutting-edge technological advancements in the global Compounding pharmacy market but also the strategic plans of industry leaders.
Table of Content
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Compounding Pharmacy Market
5.1. COVID-19 Landscape: Compounding Pharmacy Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Compounding Pharmacy Market, By Therapeutic Area
8.1. Compounding Pharmacy Market, by Therapeutic Area, 2023-2032
8.1.1. Pain Management
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Hormone Replacement
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Dermal Disorders
8.1.3.1. Market Revenue and Forecast (2020-2032)
8.1.4. Nutritional Supplements
8.1.4.1. Market Revenue and Forecast (2020-2032)
8.1.5. Others
8.1.5.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Compounding Pharmacy Market, By Route of Administration
9.1. Compounding Pharmacy Market, by Route of Administration, 2023-2032
9.1.1. Oral
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Topical
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Parenteral
9.1.3.1. Market Revenue and Forecast (2020-2032)
9.1.4. Others
9.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Compounding Pharmacy Market, By Application
10.1. Compounding Pharmacy Market, by Application, 2023-2032
10.1.1. Pediatric
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Geriatric
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Adult
10.1.3.1. Market Revenue and Forecast (2020-2032)
10.1.4. Veterinary
10.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Compounding Pharmacy Market, By Compounding Type
11.1. Compounding Pharmacy Market, by Compounding Type, 2023-2032
11.1.1. Pharmaceutical Dosage Alteration (PDA)
11.1.1.1. Market Revenue and Forecast (2020-2032)
11.1.2. Pharmaceutical Ingredient Alteration (PIA)
11.1.2.1. Market Revenue and Forecast (2020-2032)
11.1.3. Currently Unavailable Pharmaceutical Manufacturing (CUPM)
11.1.3.1. Market Revenue and Forecast (2020-2032)
11.1.4. Others
11.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 12. Global Compounding Pharmacy Market, By Sterility
12.1. Compounding Pharmacy Market, by Sterility, 2023-2032
12.1.1. Sterile
12.1.1.1. Market Revenue and Forecast (2020-2032)
12.1.2. Non-sterile
12.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 13. Global Compounding Pharmacy Market, By Distribution Channel
13.1. Compounding Pharmacy Market, by Distribution Channel, 2023-2032
13.1.1. Compounding Pharmacy
13.1.1.1. Market Revenue and Forecast (2020-2032)
13.1.2. Hospital Pharmacy
13.1.2.1. Market Revenue and Forecast (2020-2032)
13.1.3. Others
13.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 14. Global Compounding Pharmacy Market, Regional Estimates and Trend Forecast
14.1. North America
14.1.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
14.1.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
14.1.3. Market Revenue and Forecast, by Application (2020-2032)
14.1.4. Market Revenue and Forecast, by Compounding Type (2020-2032)
14.1.5. Market Revenue and Forecast, by Sterility (2020-2032)
14.1.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)
14.1.7. U.S.
14.1.7.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
14.1.7.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
14.1.7.3. Market Revenue and Forecast, by Application (2020-2032)
14.1.7.4. Market Revenue and Forecast, by Compounding Type (2020-2032)
14.1.8. Market Revenue and Forecast, by Sterility (2020-2032)
14.1.8.1. Market Revenue and Forecast, by Distribution Channel (2020-2032)
14.1.9. Rest of North America
14.1.9.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
14.1.9.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
14.1.9.3. Market Revenue and Forecast, by Application (2020-2032)
14.1.9.4. Market Revenue and Forecast, by Compounding Type (2020-2032)
14.1.10. Market Revenue and Forecast, by Sterility (2020-2032)
14.1.11. Market Revenue and Forecast, by Distribution Channel (2020-2032)
14.1.11.1.
14.2. Europe
14.2.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
14.2.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
14.2.3. Market Revenue and Forecast, by Application (2020-2032)
14.2.4. Market Revenue and Forecast, by Compounding Type (2020-2032)
14.2.5. Market Revenue and Forecast, by Sterility (2020-2032)
14.2.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)
14.2.7.
14.2.8. UK
14.2.8.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
14.2.8.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
14.2.8.3. Market Revenue and Forecast, by Application (2020-2032)
14.2.9. Market Revenue and Forecast, by Compounding Type (2020-2032)
14.2.10. Market Revenue and Forecast, by Sterility (2020-2032)
14.2.10.1. Market Revenue and Forecast, by Distribution Channel (2020-2032)
14.2.11. Germany
14.2.11.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
14.2.11.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
14.2.11.3. Market Revenue and Forecast, by Application (2020-2032)
14.2.12. Market Revenue and Forecast, by Compounding Type (2020-2032)
14.2.13. Market Revenue and Forecast, by Sterility (2020-2032)
14.2.14. Market Revenue and Forecast, by Distribution Channel (2020-2032)
14.2.14.1.
14.2.15. France
14.2.15.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
14.2.15.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
14.2.15.3. Market Revenue and Forecast, by Application (2020-2032)
14.2.15.4. Market Revenue and Forecast, by Compounding Type (2020-2032)
14.2.16. Market Revenue and Forecast, by Sterility (2020-2032)
14.2.16.1. Market Revenue and Forecast, by Distribution Channel (2020-2032)
14.2.17. Rest of Europe
14.2.17.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
14.2.17.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
14.2.17.3. Market Revenue and Forecast, by Application (2020-2032)
14.2.17.4. Market Revenue and Forecast, by Compounding Type (2020-2032)
14.2.18. Market Revenue and Forecast, by Sterility (2020-2032)
14.2.18.1. Market Revenue and Forecast, by Distribution Channel (2020-2032)
14.3. APAC
14.3.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
14.3.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
14.3.3. Market Revenue and Forecast, by Application (2020-2032)
14.3.4. Market Revenue and Forecast, by Compounding Type (2020-2032)
14.3.5. Market Revenue and Forecast, by Sterility (2020-2032)
14.3.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)
14.3.7. India
14.3.7.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
14.3.7.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
14.3.7.3. Market Revenue and Forecast, by Application (2020-2032)
14.3.7.4. Market Revenue and Forecast, by Compounding Type (2020-2032)
14.3.8. Market Revenue and Forecast, by Sterility (2020-2032)
14.3.9. Market Revenue and Forecast, by Distribution Channel (2020-2032)
14.3.10. China
14.3.10.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
14.3.10.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
14.3.10.3. Market Revenue and Forecast, by Application (2020-2032)
14.3.10.4. Market Revenue and Forecast, by Compounding Type (2020-2032)
14.3.11. Market Revenue and Forecast, by Sterility (2020-2032)
14.3.11.1. Market Revenue and Forecast, by Distribution Channel (2020-2032)
14.3.12. Japan
14.3.12.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
14.3.12.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
14.3.12.3. Market Revenue and Forecast, by Application (2020-2032)
14.3.12.4. Market Revenue and Forecast, by Compounding Type (2020-2032)
14.3.12.5. Market Revenue and Forecast, by Sterility (2020-2032)
14.3.12.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)
14.3.13. Rest of APAC
14.3.13.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
14.3.13.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
14.3.13.3. Market Revenue and Forecast, by Application (2020-2032)
14.3.13.4. Market Revenue and Forecast, by Compounding Type (2020-2032)
14.3.13.5. Market Revenue and Forecast, by Sterility (2020-2032)
14.3.13.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)
14.4. MEA
14.4.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
14.4.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
14.4.3. Market Revenue and Forecast, by Application (2020-2032)
14.4.4. Market Revenue and Forecast, by Compounding Type (2020-2032)
14.4.5. Market Revenue and Forecast, by Sterility (2020-2032)
14.4.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)
14.4.7. GCC
14.4.7.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
14.4.7.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
14.4.7.3. Market Revenue and Forecast, by Application (2020-2032)
14.4.7.4. Market Revenue and Forecast, by Compounding Type (2020-2032)
14.4.8. Market Revenue and Forecast, by Sterility (2020-2032)
14.4.9. Market Revenue and Forecast, by Distribution Channel (2020-2032)
14.4.10. North Africa
14.4.10.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
14.4.10.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
14.4.10.3. Market Revenue and Forecast, by Application (2020-2032)
14.4.10.4. Market Revenue and Forecast, by Compounding Type (2020-2032)
14.4.11. Market Revenue and Forecast, by Sterility (2020-2032)
14.4.12. Market Revenue and Forecast, by Distribution Channel (2020-2032)
14.4.13. South Africa
14.4.13.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
14.4.13.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
14.4.13.3. Market Revenue and Forecast, by Application (2020-2032)
14.4.13.4. Market Revenue and Forecast, by Compounding Type (2020-2032)
14.4.13.5. Market Revenue and Forecast, by Sterility (2020-2032)
14.4.13.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)
14.4.14. Rest of MEA
14.4.14.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
14.4.14.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
14.4.14.3. Market Revenue and Forecast, by Application (2020-2032)
14.4.14.4. Market Revenue and Forecast, by Compounding Type (2020-2032)
14.4.14.5. Market Revenue and Forecast, by Sterility (2020-2032)
14.4.14.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)
14.5. Latin America
14.5.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
14.5.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
14.5.3. Market Revenue and Forecast, by Application (2020-2032)
14.5.4. Market Revenue and Forecast, by Compounding Type (2020-2032)
14.5.5. Market Revenue and Forecast, by Sterility (2020-2032)
14.5.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)
14.5.7. Brazil
14.5.7.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
14.5.7.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
14.5.7.3. Market Revenue and Forecast, by Application (2020-2032)
14.5.7.4. Market Revenue and Forecast, by Compounding Type (2020-2032)
14.5.8. Market Revenue and Forecast, by Sterility (2020-2032)
14.5.8.1. Market Revenue and Forecast, by Distribution Channel (2020-2032)
14.5.9. Rest of LATAM
14.5.9.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
14.5.9.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
14.5.9.3. Market Revenue and Forecast, by Application (2020-2032)
14.5.9.4. Market Revenue and Forecast, by Compounding Type (2020-2032)
14.5.9.5. Market Revenue and Forecast, by Sterility (2020-2032)
14.5.9.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)
Chapter 15. Company Profiles
15.1. Fresenius Kabi
15.1.1. Company Overview
15.1.2. Product Offerings
15.1.3. Financial Performance
15.1.4. Recent Initiatives
15.2. Fagron NV
15.2.1. Company Overview
15.2.2. Product Offerings
15.2.3. Financial Performance
15.2.4. Recent Initiatives
15.3. B. Braun Medical Inc.
15.3.1. Company Overview
15.3.2. Product Offerings
15.3.3. Financial Performance
15.3.4. Recent Initiatives
15.4. Rx3 Compounding Pharmacy
15.4.1. Company Overview
15.4.2. Product Offerings
15.4.3. Financial Performance
15.4.4. Recent Initiatives
15.5. Clinigen Group PLC
15.5.1. Company Overview
15.5.2. Product Offerings
15.5.3. Financial Performance
15.5.4. Recent Initiatives
15.6. Dougherty’s Pharmacy, Inc.
15.6.1. Company Overview
15.6.2. Product Offerings
15.6.3. Financial Performance
15.6.4. Recent Initiatives
15.7. Lorraine’s Pharmacy
15.7.1. Company Overview
15.7.2. Product Offerings
15.7.3. Financial Performance
15.7.4. Recent Initiatives
15.8. Wedgewood Pharmacy
15.8.1. Company Overview
15.8.2. Product Offerings
15.8.3. Financial Performance
15.8.4. Recent Initiatives
15.9. Institutional Pharmacy Solutions
15.9.1. Company Overview
15.9.2. Product Offerings
15.9.3. Financial Performance
15.9.4. Recent Initiatives
15.10. Mcguff compounding pharmacy services
15.10.1. Company Overview
15.10.2. Product Offerings
15.10.3. Financial Performance
15.10.4. Recent Initiatives
Chapter 16. Research Methodology
16.1. Primary Research
16.2. Secondary Research
16.3. Assumptions
Chapter 17. Appendix
17.1. About Us
17.2. Glossary of Terms
About Us:
Our team comprises a dedicated group of research analysts and management consultants who are driven by a unified vision: assisting individuals and organizations in realizing their strategic objectives, both immediate and long-term, through the provision of comprehensive research services. At Precedence Research, we have positioned ourselves to cater to the needs of a diverse range of entities, including established companies, startups, and non-profit organizations across various sectors. Our expertise extends to industries such as packaging, automotive, healthcare, chemicals and materials, industrial automation, consumer products, electronics and semiconductors, IT and telecommunications, and energy. With a wealth of experience within our ranks, our skilled analysts are equipped with extensive knowledge of the research landscape.
Contact Us
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
